Document Detail


A TAD better for myeloma therapy?
MedLine Citation:
PMID:  20150417     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
In this issue of Blood, Lokhorst and colleagues report on the results of HOVON-50, a phase 3 randomized trial designed to evaluate the effects of thalidomide during induction treatment and as maintenance in patients with multiple myeloma. There were 556 patients randomly assigned either to 3 cycles of VAD or to TAD. All patients were to receive high-dose melphalan with autologous stem cell support followed by maintenance with interferon for the VAD arm or thalidomide for the TAD arm.(1) This study together with other randomized and nonrandomized trials establish a definitive role for thalidomide as induction therapy in conjunction with dexamethasone, anthracyclines, and alkylating agents.
Authors:
Sergio Giralt
Related Documents :
15767267 - Utility of testing for monoclonal bands in serum of patients with suspected osteoporosi...
8520517 - Current therapy of refractory multiple myeloma.
12045487 - Genotypic and phenotypic analyses of hiv-1 in antiretroviral-experienced patients treat...
12685887 - Natural history of hyperlactataemia in human immunodeficiency virus-1-infected patients...
15509917 - Vagus nerve stimulation for refractory epilepsy: a transatlantic experience.
11587207 - Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chr...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Blood     Volume:  115     ISSN:  1528-0020     ISO Abbreviation:  Blood     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-02-12     Completed Date:  2010-03-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1109-10     Citation Subset:  -    
Affiliation:
M. D. Anderson Cancer Center, TX, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A synthetic circuit for selectively arresting daughter cells to create aging populations.
Next Document:  NK-cell education: KIR-S come into play.